Overview

This trial is active, not recruiting.

Conditions influenza-like illness, influenzal acute respiratory infection
Sponsor Lieselot Houspie
Start date February 2012
End date December 2013
Trial size 300 participants
Trial identifier NCT01687816, S53729

Summary

This is a prospective specimen collection study targeting patients presenting with Influenza Like Illness (ILI) and/or Acute Respiratory Infection (ARI) in an out-patient setting. A non-invasive, user friendly sampling technique, using midturbinate flocked swabs will be used. These nasal swabs will be collected in different volumes of viral transport media (0.5mL and 3.0mL), for different dilution range of the viruses present in the collected biological specimen. The collection of nasal swabs samples will support the optimization of point of care detection methods for respiratory viruses responsible for ILI and/or ARI.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective prospective
Arm
Only a nasal swab is collected, no therapeutic interventions

Primary Outcomes

Measure
Nasal swab collection of left and right nostril
time frame: 1 day

Secondary Outcomes

Measure
Completion of questionnaire
time frame: 1 day

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Male or Female - All Ages - Valid Informed Consent and/or Assent, where applicable - Onset of ILI and/or ARI within the last 3 days (≤ 72h) - Patient presented with ILI and/or ARI Exclusion Criteria: - Invalid Informed Consent and/or Assent - Onset of ILI and/or ARI was > 3 days (> 72 h) - Patient did not presented with neither ILI or ARI - Patient received intranasal attenuated influenza virus in last 3 weeks (example FluMist®, Fluenz®) - Patient received treatment with influenza direct antivirals in the last 7 days

Additional Information

Official title Prospective, Nasal Specimen Collection Study in Patients Presenting With Influenza Like Illness and/or Acute Respiratory Infection in an Outpatient Setting
Principal investigator Marc Van Ranst, M.D., PhD
Trial information was received from ClinicalTrials.gov and was last updated in September 2012.
Information provided to ClinicalTrials.gov by Universitaire Ziekenhuizen Leuven.